Skip to main content

The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy

Cancer Chemotherapy and Pharmacology volume 53, pages 123–128 (2004)Cite this article

Abstract

Objectives

To assess the cardiovascular safety, tolerability and efficacy of high doses of granisetron for the treatment of nausea and vomiting in patients undergoing highly emetogenic chemotherapy.

Methods

Patients with histologically confirmed malignant disease were given an intravenous infusion of granisetron, 160 μg/kg, over 30 min, starting 15 min after highly emetogenic chemotherapy. Patients underwent cardiac monitoring for 24 h following the granisetron infusion. Pulse, blood pressure and electrocardiogram (lead II and ambulatory) measurements were taken, and routine clinical chemistry and haematology tests performed. Blood samples for pharmacokinetic analysis were taken before the granisetron infusion, and at intervals afterwards. Adverse events were self-assessed using a symptom checklist. Self-assessment categorical rating scales were used to evaluate patient nausea, vomiting and retching.

Results

Ten patients (eight females and two males; average age 41.5 years) completed the trial and were included in the safety and efficacy assessments. No clinically relevant changes in electrocardiogram, pulse rate, blood pressure or laboratory parameters were observed. Furthermore, in the 7 days following dosing there were no serious adverse events leading to withdrawal from the trial. A complete response (no vomiting, retching or, at most, mild nausea) was experienced by five patients. Six patients had no, or mild, nausea and an additional two patients vomited on a maximum of two occasions. Additional antiemetic rescue medication was given to three patients during the 24-h trial period. Despite considerable interpatient variability, Cmax and AUC parameters were proportionally greater than values reported for lower doses of granisetron.

Conclusions

Granisetron administered at four times the upper recommended dose demonstrated good efficacy and tolerability with no clinically important cardiac effects.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Addelman M, Erlichman C, Fine S, Warr D, Murray C (1990) Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 8:337

    CAS  PubMed  Google Scholar 

  2. Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J (1991) QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 83:1888

    CAS  PubMed  Google Scholar 

  3. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Riviere A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Greve J, Diaz-Rubio E, Seitz JF (1996) A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur J Cancer 32A:807

    Article  CAS  PubMed  Google Scholar 

  4. Baltzer L, Kris MG, Hinkley L, Pisters K, Lacava PV, Pierri MK, Rigas JR, Grant SC, Gralla RJ, Grunberg S, Hahne W (1994) Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae? (abstract 1489). Proc Am Soc Clin Oncol 13:433

    Google Scholar 

  5. Bleiberg HH, Speilmann M, Falkson G, Romain D (1995) Anti-emetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose ranging study. Clin Ther 17:38

    Article  CAS  PubMed  Google Scholar 

  6. Boike SC, Ilson B, Zariffa N, Jorkasky DK (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 54:1172

    CAS  Google Scholar 

  7. Carmichael J, Cantwell BMJ, Edwards CM, Zussman BD, Thompson S, Rapeport WG, Harris AL (1989) A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 24:45

    CAS  PubMed  Google Scholar 

  8. Carmichael J, Philip PA, Forfar C, Harris AL (1995) An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 37:134

    Article  CAS  PubMed  Google Scholar 

  9. Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE (1998) Use of granisetron in patients refractory to previous treatment with anti-emetics. Anticancer Drugs 9:381

    CAS  PubMed  Google Scholar 

  10. Clarkson A, Coates PE, Zussman BD (1988) A specific HPLC method for the determination of BRL 43694 in plasma and urine. Br J Clin Pharmacol 25:136

    Google Scholar 

  11. Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419

    Google Scholar 

  12. Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group Study. J Natl Cancer Inst 83:1077

    CAS  PubMed  Google Scholar 

  13. de Wit R, de Boer AC, Linden GHM, Stoter G, Sparreboom A, Verweij J (2001) Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 85:1099

    Article  PubMed  Google Scholar 

  14. Doherty KM (1999) Closing the gap in prophylactic anti-emetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3:113

    CAS  PubMed  Google Scholar 

  15. Ewer MS, Benjamin RS (1997) Cardiac complications. In: Holland JF, Bast RC, Morton DL, et al (eds) Cancer medicine, 4th edn. Williams and Wilkins, Baltimore, p 3197

  16. Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41:400

    CAS  PubMed  Google Scholar 

  17. Goodin S, Cunningham R (2002) 5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 7:424

    CAS  PubMed  Google Scholar 

  18. Gralla RJ (1994) Anti-emetic treatment for cancer chemotherapy: problems and progress. Support Cancer Care 2:275

    CAS  Google Scholar 

  19. Hacking A (1992) Oral granisetron—simple and effective: a preliminary report. The Granisetron Study Group. Eur J Cancer 28A [Suppl 1]:S28

  20. Hall SW, Mailliard J, Ritter H, Friedman C, Palmer R (1995) Intravenous granisetron 10 and 40 mcg/kg prevent nausea and vomiting during multiple cycles of highly emetogenic cisplatin-based chemotherapy. Proc Am Soc Clin Oncol 14:528

    Google Scholar 

  21. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W (1996) Double-blind, randomized comparison of the anti-emetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242

    CAS  PubMed  Google Scholar 

  22. Jantunen IT, Kataja VV, Muhonen TT, Parviainen T (1996) Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 37:502

    CAS  Google Scholar 

  23. Kamanabrou D, on behalf of the Granisetron Study Group (1992) Intravenous granisetron—establishing the optimal dose. Eur J Cancer 28A:S6

    PubMed  Google Scholar 

  24. Keefe DL (2000) Cardiovascular emergencies in the cancer patient. Semin Oncol 27:244

    CAS  PubMed  Google Scholar 

  25. Keefe DL (2002) The cardiotoxic potential of the 5-HT3 receptor antagonist anti-emetics: is there cause for concern? Oncologist 7:65

    CAS  PubMed  Google Scholar 

  26. Laszlo J (1983) Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J (ed) Anti-emetics and cancer chemotherapy. Williams and Wilkins, Baltimore London, p 1

  27. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966

    CAS  PubMed  Google Scholar 

  28. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204

    CAS  PubMed  Google Scholar 

  29. O’Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F (1993) Impact of chemotherapy-associated nausea and vomiting on patients’ functional status and on costs: survey of five Canadian centres. Can Med Assoc J 149:296

    CAS  Google Scholar 

  30. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754

    CAS  PubMed  Google Scholar 

  31. Ritter HL, Gralla MJ, Hall SW, Wada JK, Friedman C, Hand L, Fitts D (1998) Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer Invest 16:87

    CAS  PubMed  Google Scholar 

  32. Riviere A, on behalf of the Granisetron Study Group (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967

    CAS  PubMed  Google Scholar 

  33. Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, DiCostanzo F, Donati D, Ballatori E, Tognoni G (1987) Anti-emetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5:141

    CAS  PubMed  Google Scholar 

  34. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 333:1004

    Article  PubMed  Google Scholar 

  35. Schmitt R (1993) Quality of life issues in lung cancer. New symptom management strategies. Chest [Suppl] 103:51S

    Google Scholar 

  36. Soukop M (1994) A dose-finding study of granisetron, a novel anti-emetic, in patients receiving high-dose cisplatin. Support Care Cancer 2:177

    CAS  PubMed  Google Scholar 

  37. Upward JW, Arnold BDC, Link C, Pierce DM, Allen A, Tasker TCG (1990) The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer 26 [Suppl 1]:S12

  38. Veehof LF, Stewart R, Haaijer-Ruskamp FM, Meyboom-de Jong B (1999) Chronic polypharmacy in one-third of the elderly in family practice. Ned Tijdschr Geneeskd 143:93

    CAS  PubMed  Google Scholar 

  39. Wei JY (1995) Cardiovascular comorbidity in the older cancer patient. Semin Oncol 22 [Suppl 1]:9

  40. Yancik R (1997) Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80:1273

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by a grant from Beecham Pharmaceuticals. The article was supported (in part) by Hoffmann-La Roche.

Author information

Affiliations

  1. Department of Clinical Oncology, City Hospital, University of Nottingham, Cancer Research UK, Hucknall Road, Nottingham, NG5 1PB, UK

    James Carmichael

  2. Department of Clinical Oncology, Churchill Hospital, Cancer Research UK, Oxford, OX3 7LJ, UK

    Adrian L. Harris

Authors
  1. James Carmichael
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian L. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carmichael, J., Harris, A.L. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol 53, 123–128 (2004). https://doi.org/10.1007/s00280-003-0689-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0689-6

Keywords

  • Emesis
  • Granisetron
  • Highly emetogenic chemotherapy
  • Cardiovascular safety
  • Tolerability